Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : GelTex Pharmaceuticals (GELX) -- Ignore unavailable to you. Want to Upgrade?

To: Robert L. Ray who wrote (94)	10/28/1998 7:16:00 PM
From: ADEL 7	Read Replies (1) \| Respond to of 127

calcium carbonate (OTC) is used more than calcium acetate for sure. Some hospitals offer only Ca CO3 as a phosphate binder for their patients. In my previous message , clearly I wrote that Renalgel, not PhosLo, will be used for a subset of dialysis patients. Please read it again. Most patients do not like any medication in liquid or gel form. To claim that the market value for Renalgel is 200-300 million dollars is just not possible. I am trying to be helpful. It is a stock to short for sure. I said that when it was $31/share in 1997 and I was right. Just wait and see. Take care Adel7